Recently Featured

Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M

March 8, 2026
Bioxytran has announced promising results from its phase 1b/2a clinical trial of ProLectin-M, an antiviral candidate aimed at treating mild to moderate COVID-19. The early data indicate that patients receiving ProLectin-M experienced faster viral clearance compared to those on placebo, alongside a favorable safety profile. This development is significant as it highlights the potential for…

Pharma Giants Prioritize Employee Safety and Supply Chain Stability Amid Middle East Conflict

March 8, 2026
As the United States and Israel’s recent military actions against Iran create significant geopolitical tensions, major pharmaceutical companies are closely monitoring the safety of their employees in the region. These companies are not only assessing the immediate risks to their workforce but are also taking proactive steps to ensure continued access to medicines in neighboring…

Category Lists Established Under Windsor Framework Set to Impact Pharma Sector by 2025

March 8, 2026
A comprehensive list of individual human medicinal products will be implemented on January 1, 2025, as part of the new arrangements established by the Windsor Framework. This framework aims to streamline regulatory processes and enhance the movement of goods between the UK and the EU, particularly in the pharmaceutical sector. The introduction of these category…

Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19

March 8, 2026
Bioxytran, Inc. recently announced promising results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study of oral ProLectin-M in hospitalized patients with mild to moderate COVID-19. The study demonstrated that the highest evaluated dose of ProLectin-M (16,800 mg/day) led to statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared to placebo,…

Ongoing Cases